Cargando…

A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years

Objective: To investigate the ability of a MRI-based radiomics-clinicopathological model to predict pituitary macroadenoma (PMA) recurrence within 5 years. Materials and Methods: We recruited 74 recurrent and 94 non-recurrent subjects, following first surgery with 5-year follow-up data. Univariate a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Luo, Yuqi, Kong, Xin, Wan, Tao, Long, Yunling, Ma, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767054/
https://www.ncbi.nlm.nih.gov/pubmed/35069413
http://dx.doi.org/10.3389/fneur.2021.780628
_version_ 1784634648422252544
author Zhang, Yu
Luo, Yuqi
Kong, Xin
Wan, Tao
Long, Yunling
Ma, Jun
author_facet Zhang, Yu
Luo, Yuqi
Kong, Xin
Wan, Tao
Long, Yunling
Ma, Jun
author_sort Zhang, Yu
collection PubMed
description Objective: To investigate the ability of a MRI-based radiomics-clinicopathological model to predict pituitary macroadenoma (PMA) recurrence within 5 years. Materials and Methods: We recruited 74 recurrent and 94 non-recurrent subjects, following first surgery with 5-year follow-up data. Univariate and multivariate analyses were conducted to identify independent clinicopathological risk factors. Two independent and blinded neuroradiologists used 3D-Slicer software to manually delineate whole tumors using preoperative axial contrast-enhanced T1WI (CE-T1WI) images. 3D-Slicer was then used to extract radiomics features from segmented tumors. Dimensionality reduction was carried out by the least absolute shrinkage and selection operator (LASSO). Two multilayer perceptron (MLP) models were established, including independent clinicopathological risk factors (Model 1) and a combination of screened radiomics features and independent clinicopathological markers (Model 2). The predictive performance of these models was evaluated by receiver operator characteristic (ROC) curve analysis. Results: In total, 1,130 features were identified, and 4 of these were selected by LASSO. In the test set, the area under the curve (AUC) of Model 2 was superior to Model 1 {0.783, [95% confidence interval (CI): 0.718—.860] vs. 0.739, (95% CI: 0.665–0.818)}. Model 2 also yielded the higher accuracy (0.808 vs. 0.692), sensitivity (0.826 vs. 0.652), and specificity (0.793 vs. 0.724) than Model 1. Conclusions: The integrated classifier was superior to a clinical classifier and may facilitate the prediction of individualized prognosis and therapy.
format Online
Article
Text
id pubmed-8767054
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87670542022-01-20 A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years Zhang, Yu Luo, Yuqi Kong, Xin Wan, Tao Long, Yunling Ma, Jun Front Neurol Neurology Objective: To investigate the ability of a MRI-based radiomics-clinicopathological model to predict pituitary macroadenoma (PMA) recurrence within 5 years. Materials and Methods: We recruited 74 recurrent and 94 non-recurrent subjects, following first surgery with 5-year follow-up data. Univariate and multivariate analyses were conducted to identify independent clinicopathological risk factors. Two independent and blinded neuroradiologists used 3D-Slicer software to manually delineate whole tumors using preoperative axial contrast-enhanced T1WI (CE-T1WI) images. 3D-Slicer was then used to extract radiomics features from segmented tumors. Dimensionality reduction was carried out by the least absolute shrinkage and selection operator (LASSO). Two multilayer perceptron (MLP) models were established, including independent clinicopathological risk factors (Model 1) and a combination of screened radiomics features and independent clinicopathological markers (Model 2). The predictive performance of these models was evaluated by receiver operator characteristic (ROC) curve analysis. Results: In total, 1,130 features were identified, and 4 of these were selected by LASSO. In the test set, the area under the curve (AUC) of Model 2 was superior to Model 1 {0.783, [95% confidence interval (CI): 0.718—.860] vs. 0.739, (95% CI: 0.665–0.818)}. Model 2 also yielded the higher accuracy (0.808 vs. 0.692), sensitivity (0.826 vs. 0.652), and specificity (0.793 vs. 0.724) than Model 1. Conclusions: The integrated classifier was superior to a clinical classifier and may facilitate the prediction of individualized prognosis and therapy. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8767054/ /pubmed/35069413 http://dx.doi.org/10.3389/fneur.2021.780628 Text en Copyright © 2022 Zhang, Luo, Kong, Wan, Long and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Zhang, Yu
Luo, Yuqi
Kong, Xin
Wan, Tao
Long, Yunling
Ma, Jun
A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
title A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
title_full A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
title_fullStr A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
title_full_unstemmed A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
title_short A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years
title_sort preoperative mri-based radiomics-clinicopathological classifier to predict the recurrence of pituitary macroadenoma within 5 years
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767054/
https://www.ncbi.nlm.nih.gov/pubmed/35069413
http://dx.doi.org/10.3389/fneur.2021.780628
work_keys_str_mv AT zhangyu apreoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT luoyuqi apreoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT kongxin apreoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT wantao apreoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT longyunling apreoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT majun apreoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT zhangyu preoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT luoyuqi preoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT kongxin preoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT wantao preoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT longyunling preoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years
AT majun preoperativemribasedradiomicsclinicopathologicalclassifiertopredicttherecurrenceofpituitarymacroadenomawithin5years